Answers are grounded in this paper and cite their sources.
Polycystic ovary syndrome (PCOS) is a highly heterogeneous endocrine disorder characterized by concurrent reproductive dysfunction and metabolic abnormalities. Its core pathogenesis entails multiple pathological processes, including dysfunction of the hypothalamic-pituitary-ovarian axis, insulin resistance, hyperandrogenemia, and chronic low-grade inflammation. A growing body of evidence suggests that mitochondrial dysfunction is associated with PCOS, although the causal relationship between the two has not yet been fully elucidated. This review critically evaluates evidence from in vitro studies, animal experiments, and human trials to investigate whether mitochondrial dysfunction serves as the initiating factor, a secondary consequence, or an amplifying factor within the mitochondrial-metabolic-inflammatory axis. This review discusses the mitochondrial alterations associated with distinct phenotypes, candidate biomarkers, and the research insights derived from multi-omics and single-cell technologies; it further elucidates the underlying molecular mechanisms, the limitations of existing clinical evidence, and the practical challenges in translating mitochondrial intervention strategies into clinical practice. Mitochondrial dysfunction contributes to the establishment of a bidirectional regulatory network linking metabolic stress, inflammation, and ovarian dysfunction.
No takes yet. Share an insight, caveat, or question.
San et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: